Bolt Biotherapeutics, Inc.
BOLTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Bolt Biotherapeutics, Inc. (BOLT) is listed under Biotechnology. At a $7.7M market cap, Bolt Biotherapeutics, Inc. ranks as a micro-cap company within healthcare. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Market Cap
$7.7M
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-0.02
EPS (TTM)
$-14.95
EPS (Fwd)
$-254.96
ROE
-88.8%
ROA
-28.1%
Cash
$22.9M
Total Debt
$22.3M
Free CF
-$21.1M
52W Change
-32.4%
Annual Financials
Cash vs Debt
Where BOLT stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, BOLT finished 18.18% below its 150-day moving average ($4.95) and 19.80% below its 200-day moving average ($5.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BOLT overbought or oversold?
At the July 15, 2026 close, BOLT's RSI(14) was 42.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $22.9M in cash comfortably exceeding the $22.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$21.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -88.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $5.7M (2022) to $7.7M (2025), reflecting a 34% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bolt Biotherapeutics, Inc. and its sector.